Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2003

View Archived Issues

EACS presentations cover clinical results for atazanavir

Good hemodynamic profile associated with selodenoson in chronic atrial fibrillation

ABT-239, a nonimidazole H3 receptor antagonist with cognition-enhancing effects

NXY-059 enhances tenecteplase-induced neuroprotection in rabbits with embolic stroke

Several series of chemokine CCR3 antagonists presented by GSK

Novel glucocorticoid receptor modulators identified at Boehringer Ingelheim

Janssen claims dual 5-HT reuptake inhibitors/alpha2-adrenoceptor antagonists and their use

Recent patent covers new liver X receptor agonists discovered by GSK scientists

Schering AG presents new glucocorticoid receptor ligands

Spanish researchers design new adenosine A2A and/or A2B antagonists

New BZ receptor ligands with neurotrophic activity developed at Sanofi-Synthelabo

Eligard products receive Canadian approval

Phase IIb trials of pralnacasan in rheumatoid arthritis discontinued

Milestone reached in osteoporosis collaboration between Celltech and Amgen

Nefazodone withdrawn from market in Canada

Lexicon achieves first performance milestone in Genentech alliance

Novartis and Medicines for Malaria Venture to develop pediatric Coartem

Phase II dose-to-rash study of Tarceva

Roche acquires rights to CS-023

Savient and Teva terminate acquisition discussions

Novo Nordisk obtains license option for Islet Neogenesis Therapy

Vertex reports Q3 financial results and product pipeline update

A tetrapeptide reported effective in reducing infarct size following AMI

No adverse cardiac electrophysiological effects associated with ivabradine

Comparative study of binodenoson and adenosine in PS-SPECT

BG-9928 improves sodium excretion in heart failure patients

ETC-642 elevates HDL cholesterol in atherosclerosis

Panacea selects neuroprotective lead compound that acts by inhibiting oxidative stress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...